Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes by Zhang, J-Y, Hamey, F, Trzupek, D, Mickunas, M, Lee, M, Godfrey, L, Yang, JHM, Pekalski, ML, Kennet, J, Waldron-Lynch, F, Evans, ML, Tree, TIM, Wicker, LS, Todd, JA, Ferreira, RC

Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol by Gregory, JW, Carter, K, Cheung, WY, Holland, G, Bowen-Morris, J, Luzio, S, Dunseath, G, Tree, T, Yang, JHM, Marwaha, A, Ali, MA, Bashir, N, Hutchings, HA, Fegan, GW, Stenson, R, Hiles, S, Marques-Jones, S, Brown, A, Tatovic, D, Dayan, C